A PEER-REVIEWED JOURNAL OF RESEARCH AND CLINICAL MEDICINEISSN 1727-2378 (Print)         ISSN 2713-2994 (Online)
Ru
En

Immunotherapy for Inflammatory Bowel Disease

DOI:10.31550/1727-2378-2019-165-10-31-37
For citation: Nikonov E.L., Aksyonov V.A., Skvortsova T.A., Zharova M.E. Immunotherapy for Inflammatory Bowel Disease. Doctor.Ru. 2019; 10(165): 31–37. (in Russian) DOI: 10.31550/1727-2378-2019-165-10-31-37
11 September 11:08

Objective of the Review: To analyze data in the international literature on immunobiological medications for inflammatory bowel disease (IBD) and the treatment of IBD in pediatric patients.

Key Points: The global prevalence of IBD is about 0.3%, which causes significant economic losses, both direct and indirect. Since the 1990s, the therapeutic paradigm for IBD has changed: traditional groups of medications, which act non-selectively on targets in the immune-inflammation process, have been replaced by highly selective immunobiological medications. This review describes the main groups of immunobiological medications and outlines various treatment strategies for IBD in pediatric patients.

Conclusion: Appropriate and timely treatment of IBD, especially in pediatric practice, has been proven to reduce the risk of complications and improve quality of life.

Contribution: Nikonov, E.L. — coordination, search for references; Aksenov, V.A. — search for references, references systematization; Skvortsova, T.A. — references review, text of the article; Zharova, M.E. — search for references.

Conflict of interes: The authors declare that they do not have any conflict of interests.


E.L. Nikonov — N.I. Pirogov Russian National Research Medical University (a Federal Government-funded Educational Institution of Higher Education), Russian Ministry of Health; 1 Ostrovityanov St., Moscow, Russian Federation 117997. eLIBRARY.RU SPIN: 5618-1533. E-mail: drnikonov@mail.ru

V.A. Aksyonov — Russian Society for Evidence-based Medicine (an Interregional Public Organization); 46 Dmitrovskoye Shosse Bldg. 2, Office 17, Moscow, Russian Federation 127238. E-mail: V.Aksenov@ogp.ru

T.A. Skvortsova — Morozov City Pediatric Clinical Hospital (a Government-funded Healthcare Institution) Moscow City Department of Health; 1/9 4th Dobryninsky Pereulok, Moscow, Russian Federation 119049. eLIBRARY.RU SPIN: 6178-3323. E-mail: 79151289538@ya.ru

M.E. Zharova — N.I. Pirogov Russian National Research Medical University (a Federal Government-funded Educational Institution of Higher Education), Russian Ministry of Health; 1 Ostrovityanov St., Moscow, Russian Federation 117997. Research Institute for Healthcare Organization and Medical Management (a Government-funded Institution), Moscow City Department of Health; 30 Bolshaya Tatarskaya St., Moscow, Russian Federation 115184. eLIBRARY.RU SPIN: 4882-3634. ORCID: https://orcid.org/0000-0002-8325-5927. E-mail: zharowa.mariya@yandex.ru

Доктор.ру
11 September 11:08
LITERATURE
  1. Bernstein C.N., Eliakim A., Fedail S., Fried M., Gearry R., Goh K.L. et al.; Review Team. World Gastroenterology Organisation Global Guidelines Inflammatory Bowel Disease: Update August 2015. J. Clin. Gastroenterol. 2016; 50(10): 803–18. DOI: 10.1097/MCG.0000000000000660
  2. Ng S.C., Shi H.Y., Hamidi N., Underwood F.E., Tang W., Benchimol E.I. et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018; 390(10114): 2769–78. DOI: 10.1016/S0140-6736(17)32448-0
  3. Høivik M.L., Moum B., Solberg I.C., Henriksen M., Cvancarova M., Bernklev T. et al. Work disability in inflammatory bowel disease patients 10 years after disease onset: results from the IBSEN Study. Gut. 2013; 62(3): 368–75. DOI: 10.1136/gutjnl-2012-302311
  4. Mehta F. Report: economic implications of inflammatory bowel disease and its management. Am. J. Manag. Care. 2016; 22(3, suppl.): S51–60.
  5. de Souza H.S.P., Fiocchi C., Iliopoulos D. The IBD interactome: an integrated view of aetiology, pathogenesis and therapy. Nat. Rev. Gastroenterol. Hepatol. 2017; 14(12): 739–49. DOI: 10.1038/nrgastro.2017.110
  6. Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T. et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. 1997; 337(15): 1029–35. DOI: 10.1056/NEJM199710093371502
  7. Harbord M., Eliakim R., Bettenworth D., Karmiris K., Katsanos K., Kopylov U. et al.; European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. J. Crohns Colitis. 2017; 11(7): 769–84. DOI: 10.1093/ecco-jcc/jjx009
  8. Stidham R.W., Lee T.C., Higgins P.D., Deshpande A.R., Sussman D.A., Singal A.G. et al. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn's disease. Aliment. Pharmacol. Ther. 2014; 39(12): 1349–62. DOI: 10.1111/apt.12749
  9. Ma C., Huang V., Fedorak D.K., Kroeker K.I., Dieleman L.A., Halloran B.P. et al. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response. J. Clin. Gastroenterol. 2015; 49(8): 675–82. DOI: 10.1097/MCG.0000000000000265
  10. Sandborn W.J., Rutgeerts P., Enns R., Hanauer S.B., Colombel J.F., Panaccione R. et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann. Intern. Med. 2007; 146(12): 829–38. DOI: 10.7326/0003-4819-146-12-200706190-00159
  11. Colombel J.F., Sandborn W.J., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D. et al.; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 2010; 362(15): 1383–95. DOI: 10.1056/NEJMoa0904492
  12. Gecse K.B., Bemelman W., Kamm M.A., Stoker J., Khanna R., Ng S.C. et al.; World Gastroenterology Organization International Organisation for Inflammatory Bowel Diseases IOIBD European Society of Coloproctology and Robarts Clinical Trials. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease. Gut. 2014; 63(9): 1381–92. DOI: 10.1136/gutjnl-2013-306709
  13. Downey C. Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: A literature review. Int. J. Rheum Dis. 2016; 19(6): 536–50. DOI: 10.1111/1756-185X.12659
  14. Cleynen I., Van Moerkercke W., Billiet T., Vandecandelaere P., Vande Casteele N., Breynaert C. et al. Characteristics of Skin Lesions Associated With Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort Study. Ann. Intern. Med. 2016; 164(1): 10–22. DOI: 10.7326/M15-0729
  15. Kemanetzoglou E., Andreadou E. CNS Demyelination with TNF-α Blockers. Curr. Neurol. Neurosci. Rep. 2017; 17(4): 36. DOI: 10.1007/s11910-017-0742-1
  16. Lichtenstein G.R., Feagan B.G., Cohen R.D., Salzberg B.A., Diamond R.H., Chen D.M. et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin. Gastroenterol. Hepatol. 2006; 4(5): 621–30. DOI: 10.1016/j.cgh.2006.03.002
  17. Lichtenstein G.R., Feagan B.G., Cohen R.D., Salzberg B.A., Diamond R.H., Langholff W. et al. Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry. Am. J. Gastroenterol. 2014; 109(2): 212–23. DOI: 10.1038/ajg.2013.441
  18. Siegel C.A., Marden S.M., Persing S.M., Larson R.J., Sands B.E. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin. Gastroenterol. Hepatol. 2009; 7(8): 874–81. DOI: 10.1016/j.cgh.2009.01.004
  19. Kotlyar D.S., Osterman M.T., Diamond R.H., Porter D., Blonski W.C., Wasik M. et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 2011; 9(1): 36–41.e1. DOI: 10.1016/j.cgh.2010.09.016
  20. Sandborn W.J., van Assche G., Reinisch W., Colombel J.F., D'Haens G., Wolf D.C. et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 2012; 142(2): 257–65.e1–3. DOI: 10.1053/j.gastro.2011.10.032
  21. Fuss I.J., Becker C., Yang Z., Groden C., Hornung R.L., Heller F. et al. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm. Bowel Dis. 2006;12(1):9–15. DOI: 10.1097/01.mib.0000194183.92671.b6
  22. De Nitto D., Sarra M., Cupi M.L., Pallone F., Monteleone G. Targeting IL-23 and Th17-cytokines in inflammatory bowel diseases. Curr. Pharm. Des. 2010; 16(33): 3656–60.
  23. Feagan B.G., Sandborn W.J., Gasink C., Jacobstein D., Lang Y., Friedman J.R. et al.; UNITI–IM-UNITI Study Group. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. N. Engl. J. Med. 2016; 375(20): 1946–60. DOI: 10.1056/NEJMoa1602773
  24. Wils P., Bouhnik Y., Michetti P., Flourie B., Brixi H., Bourrier A. et al.; Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif. Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients with Crohn's Disease Refractory to Anti-Tumor Necrosis Factor Agents. Clin. Gastroenterol. Hepatol. 2016; 14(2): 242–50.e1–2. DOI: 10.1016/j.cgh.2015.09.018
  25. Nelson S.M., Nguyen T.M., McDonald J.W., MacDonald J.K. Natalizumab for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 2018; 8: CD006097. DOI: 10.1002/14651858.CD006097.pub3
  26. Feagan B.G., Rutgeerts P., Sands B.E., Hanauer S., Colombel J.F., Sandborn W.J. et al.; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 2013; 369(8): 699–710. DOI: 10.1056/NEJMoa1215734
  27. Sands B.E., Feagan B.G., Rutgeerts P., Colombel J.F., Sandborn W.J., Sy R. et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014; 147(3): 618–27.e3. DOI: 10.1053/j.gastro.2014.05.008
  28. Mosli M.H., MacDonald J.K., Bickston S.J,. Behm B.W., Tsoulis D.J., Cheng J. et al. Vedolizumab for induction and maintenance of remission in ulcerative colitis: a Cochrane systematic review and meta-analysis. Inflamm. Bowel Dis. 2015; 21(5): 1151–9. DOI: 10.1097/MIB.0000000000000396
  29. Colombel J.F., Sands B.E., Rutgeerts P., Sandborn W., Danese S., D'Haens G. et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 2017; 66(5): 839–51. DOI: 10.1136/gutjnl-2015-311079
  30. Coskun M., Salem M., Pedersen J., Nielsen O.H. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol. Res. 2013; 76: 1–8. DOI: 10.1016/j.phrs.2013.06.007
  31. Sandborn W.J., Su C., Sands B.E., D'Haens G.R., Vermeire S., Schreiber S. et al.; OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N. Engl. J. Med. 2017; 376(18): 1723–36. DOI: 10.1056/NEJMoa1606910
  32. Megan B. European Union Clears Tofacitinib for Ulcerative Colitis: @Medscape; 2019. http://www.medscape.com/viewarticle/900178 (дата обращения — 09.05.2019).
  33. Panés J., Sandborn W.J., Schreiber S., Sands B.E., Vermeire S., D'Haens G. et al. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017; 66(6): 1049–59. DOI: 10.1136/gutjnl-2016-312735
  34. Knyazev O.V., Shkurko T.V., Fadeeva N.A., Bakulin I.G., Bordin D.S. Epidemiologiya khronicheskikh vospalitel'nykh zabolevanii kishechnika. Vchera, segodnya, zavtra. Eksperim. i klin. gastroenterologiya. 2017; 3: 4–12. (in Russian)
  35. Yazvennyi kolit u detei: Klinicheskie rekomendatsii Soyuza pediatrov Rossii, 2016. URL: http://www.pediatr-russia.ru/sites/ default/files/file/kr_yk.pdf (data obrashcheniya — 15.06.2019). (in Russian)
  36. Turner D., Ruemmele F.M., Orlanski-Meyer E., Griffiths A.M., de Carpi J.M., Bronsky J. Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis-An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J. Pediatr. Gastroenterol. Nutr. 2018; 67(2): 292–310. DOI: 10.1097/MPG.0000000000002036
  37. Fedulova E.N., Tutina O.A., Fedorova O.V. i dr. Yazvennyi kolit i bolezn' Krona u detei: novye podkhody k lecheniyu. Med. al'manakh. 2008; 5: 160–3. (in Russian)
  38. Bonovas S., Nikolopoulos G.K., Lytras T., Fiorino G., Peyrin-Biroulet L., Danese S. Comparative safety of systemic and low-bioavailability steroids in inflammatory bowel disease: Systematic review and network meta-analysis. Br. J. Clin. Pharmacol. 2018; 84(2): 239–51. DOI: 10.1111/bcp.13456
  39. Timmer A., Patton P.H., Chande N., McDonald J.W., MacDonald J.K. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev. 2016; 5: CD000478. DOI: 10.1002/14651858.CD000478.pub4.
  40. Panaccione R., Ghosh S., Middleton S., Marquez J.R., Scott B.B, Flint L. et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014; 146: 392–400.e3. DOI: 10.1053/j.gastro.2013.10.052
  41. Iwanczak B.M., Kierkus J., Ryzko J., Szczepanik M., Wiecek S., Czaja-Bulsa G. et al. Induction and maintenance infliximab therapy in children with moderate to severe ulcerative colitis: Retrospective, multicenter study. Adv. Clin. Exp. Med. 2017; 26(1): 57–61. DOI: 10.17219/acem/42197
  42. Hyams J., Damaraju L., Blank M., Johanns J., Guzzo C., Winter H.S. et al.; T72 Study Group. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin. Gastroenterol. Hepatol. 2012; 10(4): 391–9.e1. DOI: 10.1016/j.cgh.2011.11.026
  43. Turner D., Griffiths A.M. Acute severe ulcerative colitis in children: a systematic review. Inflamm. Bowel Dis. 2011; 17(1): 440–9. DOI: 10.1002/ibd.21383
  44. Lawson M.M., Thomas AG., Akobeng A.K. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. 2006; 3: CD005112. DOI: 10.1002/14651858.CD005112.pub2
  45. Iwańczak B.M., Kierkuś J., Ryżko J., Szczepanik M., Więcek S., Czaja-Bulsa G. et al. Induction and maintenance infliximab therapy in children with moderate to severe ulcerative colitis: Retrospective, multicenter study. Adv. Clin. Exp. Med. 2017; 26(1): 57–61. DOI: 10.17219/acem/42197

News

30 June 00:00
A New Issue of Doctor.Ru Neurology Psychiatry, Vol. 20, No. 5 (2021), Published

Find original articles and reviews covering various aspects of neurology, psychiatry and the interview with Professor Marina Arkadievna Kinkulkina

28 June 00:00
A New Issue of Doctor.Ru Internal Medicine, Vol. 20, No. 4 (2021), Published

Find original articles and reviews covering various aspects of cardiology, gastroenterology, internal medicine and the interview with Professor Elena Zelikovna Golukhova

 

3 May 17:06
A New Issue of Doctor.Ru Pediatrics, Vol. 20, No. 3 (2021), Published

Find original articles and reviews covering various aspects of pediatrics and the interview with Professor Evgeny Grigorievich Furman

3 May 17:06
A New Issue of Doctor.Ru Endocrinology, Vol. 20, No. 2 (2021), Published

Find original articles and reviews covering various aspects of endocrinology and the interview with Professor Valentin Viktorovich Fadeev

16 April 11:57
Igor Evgenievich Khatkov joined the American Surgical Association

Igor Evgenievich Khatkov, Head of A. S. Loginov Moscow Clinical Scientific and Practical Centre, Chief Oncologist in and for Moscow is now an honoured member of the American Surgical Association.

All news